Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023-2024 Epidemic Season
Vaccines (Basel). 2024 May 17;12(5):549. doi: 10.3390/vaccines12050549. ABSTRACT Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during …